Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140
ACS Medicinal Chemistry Letters2010Vol. 2(2), pp. 124–129
Citations Over TimeTop 25% of 2010 papers
Chris P. Miller, Maysoun Shomali, C. Richard Lyttle, Louis O’Dea, Hillary Herendeen, Kyla Gallacher, Dottie Paquin, Dennis R. Compton, Bishwabhusan Sahoo, Sean A. Kerrigan, Matthew S. Burge, Michael L. Nickels, Jennifer L. Green, John A. Katzenellenbogen, Alexei Tchesnokov, Gary Hattersley
Abstract
This report describes the discovery of RAD140, a potent, orally bioavailable, nonsteroidal selective androgen receptor modulator (SARM). The characterization of RAD140 in several preclinical models of anabolic androgen action is also described.
Related Papers
- → EPI-001, A Compound Active against Castration-Resistant Prostate Cancer, Targets Transactivation Unit 5 of the Androgen Receptor(2016)154 cited
- → Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists(2011)19 cited
- → The preclinical characterization of the N-terminal domain androgen receptor inhibitor, EPI-7386, for the treatment of prostate cancer(2020)8 cited
- → Abstract 1321: Castration-resistant prostate cancer: BAY 1024767 blocks function of mutated androgen receptor.(2013)